Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT01114152 | AZD9742 Single and Multiple Ascending Dose Study in Healthy Male and Female Japanese Subjects | PHASE1 | COMPLETED | 35 | — | — | Apr 1, 2010 | Jul 1, 2010 | Aug 3, 2010 | 1 | United States |
| NCT01064388 | A Study in Healthy Volunteers to Assess Safety and Blood Levels of AZD9742 After Multiple Doses Over 14 Days | PHASE1 | COMPLETED | 36 | — | — | Feb 1, 2010 | Aug 1, 2010 | Jun 6, 2012 | 1 | United States |
| NCT01030224 | This is a Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of AZD9742 After Single IV Doses in Healthy Subjects | PHASE1 | COMPLETED | 48 | — | — | Nov 1, 2009 | Mar 1, 2010 | Jul 27, 2012 | 1 | United States |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | Dose level A, B, C and optional Dose level D and E: single administration and one to three times daily for 6 days (Japanese n=8) |
| 2 | PLACEBO_COMPARATOR | placebo given (2 subjects in each dose group) |
| AZD9742 IV Infusion | EXPERIMENTAL | Active |
| Placebo to AZD9742 IV Infusion | PLACEBO_COMPARATOR | Placebo |
| Name | Type | Description |
|---|---|---|
| AZD9742 | DRUG | IV Formulation |
| Placebo | DRUG | IV Formulation |
| Placebo to match AZD9742 | DRUG | Single IV infusion of AZD9742 placebo given to approximately 6 cohorts of 8 subjects each (6 on active and 2 on placebo) |
Inclusion Criteria: * female (non-childbearing potential) * Body mass index (BMI) : 17 to 27 kg/m 2 Exclusion Criteria: * History of any clinically significant disease or disorder which, in the opinion of the Investigator, may either put the subject at risk because of participation in the study, ...